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INTRODUCTION
It was reported that there were 8,284 new cases of lung
cancer in Korea diagnosed in 2001 (1), and the incidence
and the number of lung cancer deaths continue to increase.
Since the overall 5-yr survival for patient with lung cancer
is <15% (2), the future line in both the prevention of new
disease by reducing the prevalence of tobacco use, and being
able to accurately identify early stage disease will be amenable
to curative therapy. Saccomanno et al. (3) described the cel-
lular progression of bronchial tissue from atypical metapla-
sia to dysplasia to carcinoma in situ (CIS) and invasive carci-
noma. It has also been shown that the identification and treat-
ment of these pre-invasive lesions in other organs, such as
the cervix and colon, can lead to significant improvement in
cancer related mortality (4, 5). 
Unfortunately, early detection has not been shown to im-
prove survival in lung cancer patients, and physicians usually
do not recommend screening for lung cancer, such as sputum
cytology, chest radiology or bronchoscopy. Recent advances
in screening include the use of ultra-fast CT, serum biomark-
ers, and sputum DNA, however their role remains to be
defined (6, 7). Bronchoscopy for the detection of early lung
cancer may be helpful for two reasons: First, carcinogenesis
is slow process evolving over years (3). Secondly, about 50-
60% of all lung cancer, especially squamous cell carcinoma,
develops in the central airways. These cancers can be detect-
ed by bronchoscopy, but are generally roentgenographically
occult (8). The main problem for conventional bronchoscopy
is its low sensitivity and specificity for detection of early
malignant cancer (9). Pre-invasive lesions usually are small
and only some cell layer thick (10). Their endoscopic signs
therefore are very subtle and can be missed even by experi-
enced bronchoscopists. To improve the sensitivity and speci-
ficity of conventional endoscopy, diagnostic fluorescence pro-
cedures were developed (11). 
Autofluorescence bronchoscopy (AFB) is an emerging endo-
scopic tool that can identify pre-cancerous lesions in the cen-
tral tracheobronchial tree, predominantly squamous cell car-
cinoma. There are four available systems of AFB around the
world, but the two most widely used systems are Lung Imag-
ing Fluorescence Endoscopic device (LIFE) and D-light/AFB
system. There was only one report (12) of using LIFE, but no
report with D-light/AFB system in Korea. The aim of this
study was to compare the utility of D-Light/AFB versus the
standard white light bronchoscopy (WLB) in the detection
of pre-cancerous lesions.
MATERIALS AND METHODS
The study was done during 15 November 2001 to 31
August 2002 in Kosin University Gospel Hospital, Busan,
Korea. The criteria for enrollment were as follows: 1) patients
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Detection of Pre-invasive Endobronchial Tumors with D-light/
Autofluorescence System
Autofluorescence bronchoscopy (AFB) is one of the newly developed diagnostic
tools to detect the pre-cancerous lesions in the bronchial tissue. The utility of D-
Light/AFB in the detection of pre-cancerous lesions was compared to the standard
white light bronchoscopy (WLB). In 113 patients (male 106, female 7), who visited
hospital for evaluation of lung cancer, WLB and AFB were done and 364 biopsy
specimens were obtained from November 2001 to August 2002. The bronchoscopic
findings on WLB and AFB were compared to the pathological findings. The patho-
logic diagnoses of the specimens were as follows: normal in 96; hyperplasia in 69;
metaplasia in 32; mild dysplasia in 13, moderate dysplasia in 6, severe dysplasia in
4; carcinoma in situ in 6; invasive carcinoma in 57. The relative sensitivity of adjunc-
tive AFB to WLB vs. WLB alone was 1.5 in moderate dysplasia or worse lesions,
and 3.2 in intraepithelial neoplasia. The specificity of adjunctive AFB and WLB alone
were 0.91 and 0.5, respectively. The adjunctive AFB to the standard WLB increased
the detection rate of the localized pre-invasive lesions. However, there was high
rate of false positive in AFB.
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with known or suspected bronchogenic cancer who scheduled
for bronchoscopy as a part of standard diagnostic workup,
2) follow-up patients who were completely treated with
surgery or radiotherapy, 3) positive cytological findings, and
4) smokers older than 40 yr and/or evidence of chronic obstrac-
tive pulmonary disease. The exclusion criteria were suspected
lung infection, in state of cancer treatment, pregnancy, bleed-
ing disorders, and known reaction to topical lidocaine. 
Bronchoscopy was performed with local anesthesia with
or without sedation using D-Light/AFB (Karl Storz, Tut-
tlingen, Germany) and the standard white light bronchoscopy
(WLB: BF-1T200, Olympus, Tokyo, Japan). D-Light/AFB
system can be used without the application of a photosensi-
tive drug such as ALA. The detection of autofluorescence
was performed by flexible bronchoscopes. The color of the
normal mucosa is dominated by a green fluorescence (Fig. 1),
while malignant abnormal tissues appearing as red/brown
areas against a normal gray/blue background. Fig. 2 shows
the abnormal florescence and white light bronchoscopic find-
ings of a 74 yr old male patient with CIS in left upper lobe
bronchus. He was positive in sputum cytology, but he showed
roentgenographically occult chest radiography finding. Fig. 3
shows the pathologic finding of that patient. Details of D-
light/AFB systems have been reported elsewhere (13). The
investigation was done first with white light mode, and then
switching to blue light mode for the detection of the specific
autofluorescence. Biopsies were taken from all abnormal areas
detected by WLB and/or AFB. Additionally, in almost all
patients random biopsies were taken from normally appear-
ing bronchial tissue (2 point classification system used; nor-
mal and abnormal finding). Three more biopsy specimens
were taken in each biopsy sites. The duty pathologist with-
out knowledge of clinical findings evaluated biopsy slides
first, and then one lung pathologist who was blinded to the
previous results reviewed all. The pathologists classified the
biopsy slides based on WHO classification (14). All biopsies
were classified into one of eight groups as follows: normal,
hyperplasia, metaplasia, mild atypia, moderate atypia, severe
atypia, carcinoma in situ (CIS), and invasive carcinoma. Int-
raepithelial neoplasia was defined as lesions that were graded
as moderate/severe dysplasia or CIS. Hyperplasia or worse
was defined as including hyperplasia to invasive carcinoma.
Moderate dysplasia or worse also has the similar meaning.
The sensitivity and specificity of both bronchoscopy pro-
Fig. 1. Normal fluorescence image.
Fig. 3. Carcinoma in situ: full thickness change with cells showing
cytologic features of squamous carcinoma (H & E, ×100).
Fig. 2. Abnormal fluorescence (A, C, and D) and white light bron-
choscopic findings (B) of a 74 yr old male patient with carinoma
in situ in left upper lobe bronchus, positive in sputum cytology, but
roentgenographically occult lung cancer.
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cedures were calculated in the standard manner. Thus the
sensitivity was defined as the percentage (visually suspicious
and histologically positive/total number of histologically
positive), and specificity also by the similar way. Positive
predictive values and negative predictive values were also
calculated for both WLB and AFB in a similar manner. The
relative sensitivity, or the ratio of sensitivity of WLB+AFB
as compared with WLB alone was calculated to evaluate the
contribution of the fluorescence examination to detect neo-
plastic lesions. A relative sensitivity test >1 would indicate
a significant improvement. The data were analyzed on a per
lesion basis. For the per lesion analysis, each biopsy specimen
was evaluated and considered positive if the final diagnosis
was positive.
RESULTS
There were 113 patients (male 106, female 7) with median
age of 62 yr (range 40-80). Almost all patients (86.9%) were
current or ex-smokers with mean pack-years of 44.6 (Table 1).
A total of 364 biopsy specimens were obtained. Of these, 81
were not valuable; inflammation in 63 and inadequate speci-
mens in 18. The final pathologic diagnoses of the specimens
were as follows: Normal in 96; hyperplasia in 69; metaplasia
in 32; mild dysplasia in 13, moderate dysplasia in 6, severe
dysplasia in 4; CIS in 6; invasive carcinoma in 57 (Table 2).
Thus, 73 biopsy specimens (25.7%) were graded as moderate
dysplasia or worse; this was then used as the standard to deter-
mine the relative sensitivity in intraepithelial neoplasia of
the bronchoscopic procedure.
On the lesion-by-lesion analysis, WLB alone detected severe
dysplasia 2 among 4, CIS 2 among 6, but moderate dyspla-
sia could not be found. In addition of AFB, we missed only 1
moderate dysplasia (Table 3). The sensitivity of WLB was
30.6%, adjunctive AFB to WLB 79.2%, the specificity of
WLB 92%, adjunctive AFB to WLB 70% in hyperplasia or
worse lesions. The sensitivity of WLB was 30.6%, WLB+
AFB 79.2%, the specificity of WLB 92%, WLB+AFB 70%
Number of patients 113
Male/Female 106/7
Median age (yr) (range) 62 (40-80)
Current smoker 60 (62.5%)
Ex-smoker 26 (27.1%)
Stop year 5.12 yr ago
Start year 22.8 (10-50) yr-old
Duration (range) 37±9 yr (10-60 yr)
Pack-years (range) 44.6±15.6 (10-80) 
Indication of fluorescent bronchoscopy
Suspicion for malignancy 77 (68%)
Previous lung cancer 24 (22%)
Smoker older than 40 yr 7 (6%) 
Positive cytologic finding 5 (4%)
Table 1. Characteristics of patients
Hyperplasia/worse*
WLB WLB+AFB
MoD/worse 
WLB WLB+AFB
Sensitivity (%) 30.6 79.2 62.7 93.3
(95% CI) (23.9-37.2) (73.8-85.1) (72.4-79.6) (87.6-98.9)
False positive (%) 8 30 8.7 50
(95% CI) (2.6-13.3) (21-38.9) (4.8-12.4) (43.2-56.7)
False negative (%) 69.4 20.8 37.3 6.7
(95% CI) ( 62.7-76) (14.8-38.9) (26.3-48.2) (1-12.3)
Specificity (%) 92.0 70 93.3 50 
(95% CI) (86.6-97.3) (61-78.9) (87.5-95.1) (43.2-56.7)
True positive (%) 48.6 30.6
Relative sensitivity 2.6 1.5 
Table 3. Results of fluorescence bronchoscopy according to
histologic classification
*Hyperplasia/worse, intraepithelial neoplasia and invasive carcinoma.
MoD, moderate dysplasia; WLB, white light bronchosocpy; AFB, aut-
ofluorescence bronchoscopy. CIS, Carcinoma in situ.
Normal 96 (26.4%)
Hyperplasia 69 (19%)
Metaplasia 32 (8.8%)
Mild dysplasia 13 (3.6%)
Moderate dysplasia 6 (1.6%)
Severe dysplasia 4 (1.1%)
CIS-Microinvasive 6 (1.6%)
Invasive 57 (15.7%)
Total 283 (100%)
Table 2. Histology of biopsy specimen
HP, hyperplasia; MP, metaplasia; MiD, mild dysplasia; MoD, moderate
dysplasia; SD, severe dysplasia; CIS, carcinoma in situ; WLB, white light
bronchoscopy; AFB, autofluorescence bronchscopy.
HP MP MiD MoD SD CIS Total
WLB 
Normal 60 29 13 6 2 4 114 
Abnormal 9 3 0 0 2 2 16
AFB
Normal 21 8 5 1 0 0 35 
Abnormal 48 24 8 5 4 6 95
Total 69 32 13 6 4 6 130
Table 4. Results of WLB and FAB according to pathologic finding
Intraepithelial neoplasia, moderate dysplasia; severe dysplasia, and
carcinoma in situ. WLB, white light bronchosocpy; AFB, autofluores-
cent bronchoscopy.
WLB WLB+AFB
Sensitivity (%) 26.3 84.2
(95% CI) (6.5-46.1) (67.8-100)
Specificity (%) 91.3 50.3
(95% CI) (87.4-95.1) (43.4-57)
True positive (%) 67
Relative sensitivity 3.2
Table 5. Sensitivity, specificity, true positive, and relative sensi-
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in moderate dysplasia or worse lesions. The relative sensitivity
of adjunctive AFB to WLB vs. WLB alone was 2.6 in hyper-
plasia or worse and 1.5 in moderate dysplasia or worse lesions
(Table 4).
Of the 16 intraepithelial lesions, only 4 were by WLB
alone. The addition of the AFB identified 15 sites. There-
fore, the relative sensitivity of WLB+AFB vs. WLB alone
for intraepithelial lesions was 3.2. The specificity of adjunc-
tive AFB and WLB alone were 0.5 and 0.91, respectively
(Table 5). Fifty-seven lesions were classified as invasive car-
cinoma. 
DISCUSSION
The fluorescent system is based on the different fluores-
cence emissions of normal tissue and tumor tissue, either
spontaneously as autofluorescence (AF) light or as drug induced
fluorescence by selective accumulation of exogenous applied
photosensitizer in the tumor tissue. When a surface is illu-
minated by light, the light can be reflected, back-scattered,
or absorbed. Additionally, light also causes the tissue to flu-
oresce, however this AF can not be seen during conventional
WLB as the intensity of fluorescence is very low, and is over-
whelmed by the reflected and back-scattered light. Tissue
AF revealed the underlying biochemical changes occurring
in the cells, specifically the electronic structure of absorption
chromophores. The normal airway fluoresces green when
exposed to light in the violet-blue spectrum (400-450 nm),
and as sub-mucosal disease progresses from normal, to meta-
plasia, to dysplasia, to CIS, there is a progressive loss of the
green AF, causing a red-brown appearance of the airway wall.
This results from reductions in certain chromophores, increas-
ing thickness of the epithelium, as well as an increase in
angiogenesis that develops with more advanced disease (15).
As intraepithelial neoplastic lesions are only a few cell layers
thick, the surface mucosa typically appears relatively normal
during WLB. In fact, Woolner et al. (16) found that only
29% of CIS was visible to the experienced bronchoscopist. 
Lam et al. (17) introduced fluorescence bronchoscopy that
is effective without the use of protoporphyrins for the pur-
pose of localizing endobronchial lesions of moderate dyspla-
sia or more malignant tissue. They initially used a 100 mW
helium-cadmium laser to illuminate the airways with blue
light (442 nm). Red and green fluorescence intensities were
then measured, and expressed as a ratio. Lam’s group found
that the red/green ratios from areas with moderate dysplasia,
severe dysplasia and CIS were significantly higher than those
from normal areas (18). Their group went on to develop the
LIFE system. The system of Karl-Storz system is based on a
modified xenon light source. On a filter in the ocular of the
bronchoscope and an optional integrating camera, this can
be attached easily. There has been one study (19) comparing
LIFE and D-light system. Both systems yielded comparable
results. The examination time was significantly shorter with
the D-light system, which may be explained by the more
comfortable handling and the direct switch between white
light and AF imaging. 
When compared to the other studies, the relative sensi-
tivity of 3.2 finding rate in the intraepithelial lesion is simi-
lar. False positive rate for AFB was 41.1%, compared with
8.7% for WLB. We gained 3.2-folds sensitivity in detect-
ing pre-cancerous lesions by addition of AFB, but lost 0.55
-folds decrease in specificity. The relative sensitivity of 1.5
in moderate dysplasia or worse lesions was also similar to the
other report (20). That study was a large study with 1,173
patients (916 men) of mean age 58.7 yr using D-light sys-
tem. Overall pre-invasive lesions (moderate to severe dys-
plasia, and CIS) were detected in 3.9% of the patients. The
biopsy based sensitivity of WLB alone and WLB+AFB for
detecting intraepithelial lesion was 57.9% compared with
82.3% (1.42-fold increase). The corresponding specificity
was 62.1% compared with 58.4% (0.94-fold decrease). In
an initial study of AFB, Lam et al. found a sensitivity of 48%
for WLB, and sensitivity of 73% for AFB, a 50% improve-
ment (17). Published data in more than 1,400 patients sug-
gest that WLB alone detects on average only 40% of high-
grade dysplasia and CIS, whereas AFB increased the detec-
tion rate up to 88% (21). The variation in results of both
WLB and AFB can be explained by the quality of conven-
tional WLB as well as the reproducibility of the broncho-
scopic and pathologic interpretation (22). The latter prob-
lem will hopefully be addressed by utilizing a standardized
classification of pre-invasive lung cancer developed by the
WHO (14).
Kurie et al. (23) published a negative study. They investi-
gated the additional yield AFB had on WLB in 39 current
or former smokers, and found no significant increase in the
detection of squamous cell metaplasia or dysplasia. A possible
explanation for this is the fact that the prevalence of advanced
disease was low in the population studied. The majority of
patients were former smokers who had stopped smoking for
median of 8 yr prior to the study. This contrasts to the stud-
ies where AFB has shown to be beneficial, in that enrolled
patients had known or suspected lung cancer, and therefore
a higher prevalence of advanced dysplasia/CIS (18).
It appears that the increased sensitivity is associated with
decreased specificity, resulting in many false-positive biopsies.
Aside from the cost of the autofluorescence unit, the major
downside to AFB is the lack of specificity. The specificity of
AFB has been found to be low, with up to one third of area
of abnormal fluorescence being found to be false positives
(24). This results in a greater number of abnormal lesions
being identified at the time of bronchoscopy, prolonging the
procedure in order to biopsy the negative lesions, and added
time and expense for the pathologist, who is required to exam-
ine all of the obtained tissue (25). There are many trials to
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or combined fluorescence-reflectance imaging may also be
helpful in future bronchoscopic devices to address specifici-
ty. However it has been suggested that up to 50% of biop-
sies obtained from these areas carry molecular genetic lesions
associated with malignancy, despite their normal histologi-
cal appearance (26). 
In conclusion, the adjunctive AFB to the standard WLB
increased the detection rate of the localized pre-invasive lesions.
However, there was high rate of false positive in AFB. Our
findings do not support the general use of AFB as a screen-
ing tool for lung cancer, but suggest that it may be of use in
certain groups.
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